Gundesen MT, Schjesvold F, Lund T (2025)
Treatment of myeloma bone disease: When, how often, and for how long?
J Bone Oncol, 52, 100680
DOI 10.1016/j.jbo.2025.100680, PubMed 40242221

Richter J, Nooka A, Rodríguez-Otero P, Schjesvold F, Katodritou E, Combe E, Scott M, Cooper L, Sly I, Ballew N, Bitetti J, Boytsov N, Purser M, McNamara S (2025)
Belantamab Mafodotin Plus Proteasome Inhibition Efficacy Versus Comparators in Early Relapsed Myeloma: A Systematic Review and Network Meta-Analysis
Am J Hematol (in press)
DOI 10.1002/ajh.27661, PubMed 40143674

Askeland FB, Haukås E, Slørdahl TS, Klostergaard A, Alexandersen T, Lysén A, Abdollahi P, Nielsen LK, Hermansen E, Schjesvold F (2025)
Isatuximab, bortezomib, lenalidomide, and limited dexamethasone in patients with transplant-ineligible multiple myeloma (REST): a multicentre, single-arm, phase 2 trial
Lancet Haematol, 12 (2), e120-e127
DOI 10.1016/S2352-3026(24)00347-8, PubMed 39909655